Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
NCT06740799
This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hepatic Impairment
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Daiichi Sankyo
- Last updated on ClinicalTrials.gov
- April 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 3
- Advanced Pharma · Miami, FL
- Clinical Pharmacology of Miami, LLC · Miami, FL
- GCP Research · St. Petersburg, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.